Korro Bio Inc. (KRRO)
NASDAQ: KRRO
· Real-Time Price · USD
14.82
-2.85 (-16.13%)
At close: May 06, 2025, 3:59 PM
14.28
-3.64%
Pre-market: May 07, 2025, 04:22 AM EDT
Company Description
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases.
Korro Bio, Inc. is based in Cambridge, Massachusetts.
Korro Bio Inc.
| Country | United States |
| IPO Date | Oct 3, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 104 |
| CEO | Dr. Ram Aiyar MBA, Ph.D. |
Contact Details
Address: One Kendall Square Cambridge, Massachusetts United States | |
| Website | https://www.korrobio.com |
Stock Details
| Ticker Symbol | KRRO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001703647 |
| CUSIP Number | 500946108 |
| ISIN Number | US5009461089 |
| Employer ID | 47-2324450 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ram Aiyar MBA, Ph.D. | Chief Executive Officer, President & Director |
| Todd Chappell M.B.A. | Chief Operating Officer |
| Vineet Agarwal M.B.A. | Chief Financial Officer |
| Andrew Fraley Ph.D. | Co-Founder & Advisor |
| Dr. Joshua Rosenthal Ph.D. | Co-Founder & Advisor |
| Dr. Kemi Olugemo M.D. | Chief Medical Officer |
| Dr. Loic Vincent Ph.D. | Chief Scientific Officer |
| Jeffrey M. Cerio J.D., Pharm.D. | Senior Vice President, General Counsel & Corporate Secretary |
| Oliver Dolan | Senior Vice President of Finance & Principal Accounting Officer |
| Stephanie Engels | Senior Vice President and Head of People & Culture |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Filing |
| Apr 29, 2025 | DEF 14A | Filing |
| Apr 01, 2025 | 4 | Filing |
| Apr 01, 2025 | 4 | Filing |
| Apr 01, 2025 | 3 | Filing |
| Mar 27, 2025 | 8-K | Current Report |
| Mar 18, 2025 | S-8 | Filing |
| Mar 18, 2025 | 10-K | Annual Report |
| Mar 18, 2025 | 8-K | Current Report |